^
Association details:
| Biomarker: | FRS2 amplification |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Pemazyre (pemigatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Published date:
11/20/2020
Excerpt:
FIGHT-202 (NCT02924376), a phase II, open-label, multicenter, global study of pemigatinib in patients with previously treated advanced or metastatic cholangiocarcinoma...One of 8 patients with FRS2 amplifications achieved stable disease.
DOI:
10.1158/2159-8290.CD-20-0766
Trial ID:
Test:
